性質(zhì)

Preparation Note

Produced utilizing enriched media containing stable isotope labeled amino acids are ¹³C₆, ¹⁵N₄-labeled Arginine and ¹³C₆, ¹⁵N₂-labeled Lysine.

Infliximab Stable-Isotope Labeled Monoclonal Antibody is designed to be used as a internal standard for analysis of Infliximab in human serum.

       Reconstitution

Infliximab recovery is maximized when 0.1% formic acid is used for reconstitution of the lyophilized product.Reconstitution with other solvents may reduce recovery. Do not freeze after reconstitution.

? Briefly centrifuge the vial at ~10,000 × g to collect the product at the bottom of the vial.
? Add 500 μL of ultrapure water containing 0.1% formic acid to the vial.
? Mix the contents by gently inverting the vial a minimum of 5 times.
? Allow the vial to stａnd at room temperature for at least 15 minutes and repeat mixing by inversion.

Physical form

Each vial of Infliximab Stable-Isotope Labeled Monoclonal Antibody contains the labeled antibody in a lyophilized form containing phosphate buffered saline.

Application

Poster: Quantification of Infliximab in Human Serum by LC-MS/MS Using A Full-Length Stable Isotope Labeled Internal Standard        

General description

Infliximab Stable-Isotope Labeled Monoclonal Antibody (MSQC9) is a recombinant, stable isotope-labeled, monoclonal antibody which incorporates [¹³C₆, ¹⁵N₄]-Arginine and [¹³C₆, ¹⁵N₂]-Lysine. Expressed in CHO cells, it is designed to be used as an internal standard for the quantitative mass spectrometry analysis of Infliximab in human serum. Infliximab is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-a) and is used to treat autoimmune diseases.
Infliximab has been approved for the treatment of Crohn′s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.Infliximab Stable-Isotope Labeled Monoclonal Antibody is for research use only and is not intended for diagnostic or therapeutic use.